Overall Survival In 1st-line NSCLC Reaches 15 Months With Erbitux, Merck Serrono Informs

Data presented today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer (NSCLC) who were given Erbitux® (cetuximab) in addition to a standard 1st-line platinum-based chemotherapy lived significantly longer than those who received chemotherapy alone.1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.

More: continued here

Filed under: Lung Cancer on November 21st, 2008